Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Assessment and Tracking of Long-term Alefacept Safety


Assessment and Tracking of Long-term Alefacept (LFA-3/IgG1 Fusion Protein) Safety (ATLAS)




Subjects exposed to alefacept are to be enrolled. Subjects will be contacted every 6 months to gather general health information.

Study Status: Recruiting


Condition Intervention Phase
Psoriasis Drug: Alefacept exposure Phase 4

Verified by Astellas Pharma Inc December, 2011

Sponsored by: Astellas Pharma Inc
Information provided by: Astellas Pharma Inc identifier: NCT00454701

Study Type: Interventional

Study Design: Observational Model: Cohort, Time Perspective: Prospective

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Vice President Medical Affairs., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site